drugset

drugset / Trial / NCT00532233

SD, IL-13 Production Rate in IPF

NCT00532233 ↗

Phase 2 Completed 52 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to investigate how QAX576 affects levels of interleukin 13 (IL-13) in patients with idiopathic pulmonary fibrosis (IPF).

Timeline

Start: 2007-09
Primary completion: 2009-06
Completion: 2009-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QAX576	Monoclonal antibody	—	Intravenous

Indications